2.26
Proqr Therapeutics N V Aktie (PRQR) Neueste Nachrichten
ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Is ProQR Therapeutics N.V. a good long term investmentFree Popular Stock Recommendations - PrintWeekIndia
Is ProQR Therapeutics N.V. stock a growth or value playVerified Return Tips - Newser
Will ProQR Therapeutics N.V. stock benefit from interest rate changesAccelerated financial growth - jammulinksnews.com
What drives ProQR Therapeutics N.V. stock priceStrong return on assets - Autocar Professional
What analysts say about ProQR Therapeutics N.V. stockUnprecedented profit potential - Autocar Professional
Owning 32% shares,institutional owners seem interested in ProQR Therapeutics N.V. (NASDAQ:PRQR), - Yahoo Finance
ProQR Therapeutics N.V. Stock Analysis and ForecastDynamic investment growth - jammulinksnews.com
ProQR stock rating reiterated by Cantor Fitzgerald ahead of key 2H25 data - Investing.com Nigeria
Why ProQR Therapeutics N.V. stock attracts strong analyst attentionFree Stock Selection with 300% Return - Newser
How ProQR Therapeutics N.V. stock performs during market volatilityProven Win Setups - Newser
What makes ProQR Therapeutics N.V. stock price move sharplyFree Wealth-Building Investment Strategies - Newser
ProQR Therapeutics N.V.'s (NASDAQ:PRQR) high institutional ownership speaks for itself as stock continues to impress, up 16% over last week - simplywall.st
ProQR Therapeutics N.V. (NASDAQ:PRQR) Shares Acquired by OneDigital Investment Advisors LLC - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above Fifty Day Moving AverageWhat's Next? - MarketBeat
Vontobel Holding Ltd. Invests $48,000 in ProQR Therapeutics N.V. (NASDAQ:PRQR) - Defense World
ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces clinical hurdles - Investing.com Australia
ProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces clinical hurdles By Investing.com - Investing.com South Africa
ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Average Rating of "Buy" by Analysts - MarketBeat
ProQR Therapeutics' (PRQR) "Market Outperform" Rating Reaffirmed at JMP Securities - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Given Market Outperform Rating at JMP Securities - Defense World
PRQR: Cantor Fitzgerald Reiterates Overweight Rating | PRQR Stoc - GuruFocus
ProQR stock advances as Cantor Fitzgerald reaffirms $8 price target By Investing.com - Investing.com Canada
ProQR stock advances as Cantor Fitzgerald reaffirms $8 price target - Investing.com
ProQR submits clinical trial application for RNA editing therapy By Investing.com - Investing.com India
ProQR Seeks EU Approval for Liver Cell Protein Trial - MarketScreener
ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP - GlobeNewswire
ProQR Advances First RNA Editing Therapy to Clinical Trials for Liver Disease | PRQR Stock News - Stock Titan
Bank of America Corp DE Boosts Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics N.V. (NASDAQ:PRQR) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected - simplywall.st
Equities Analysts Offer Predictions for PRQR FY2026 Earnings - MarketBeat
Research Analysts Set Expectations for PRQR FY2026 Earnings - Defense World
Jane Street Group LLC Buys Shares of 11,400 ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Analysts Set ProQR Therapeutics (NASDAQ:PRQR) Target Price at $8.00 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Shares Sold by Two Sigma Advisers LP - Defense World
Squarepoint Ops LLC Grows Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Two Sigma Investments LP Buys 320,614 Shares of ProQR Therapeutics (NASDAQ:PRQR) - Defense World
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):